TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21761705

Group type: EXPERIMENTAL
Intervention: Oral antihistamine 10 mg everyday for one week (group CA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No loratadine tablets 10 mg everyday for one week (group CB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy controls (group D)
Number of subjects: 40
Study: 19417229

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia (60 min per day, alternating intervals of hypoxia and normoxia lasting either 3 or 5 min, for 5 consecutive days per week for 3 weeks)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no hypoxia exposure)
Number of subjects: 27
Study: 16151422

Group type: EXPERIMENTAL
Intervention: Busulfan 600 mg/m2 + cyclophosphamide 200 mg/kg
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Busulfan 16 mg/kg + cyclophosphamide 200 mg/kg + antilymphocyte globulin
Number of subjects: 94

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Busulfan 600 mg/m2
Number of subjects: 94
Study: 12875349

Group type: EXPERIMENTAL
Intervention: Test formulation (generic gliclazide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference formulation (Diamicron)
Number of subjects: 0
Study: 10647194

Group type: EXPERIMENTAL
Intervention: Melatonin (6 mg at 22.00)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Melatonin (6 mg at 22.00) + Aceten (25 mg at 18.00)
Number of subjects: 20
Study: 8690104

Group type: EXPERIMENTAL
Intervention: Spironolactone (100 mg) and oral contraceptive (150 microg desogestrel and 30 microg ethinyl E2)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cyproterone acetate (50 mg daily on days 1 to 10 of the menstrual cycle) and estrogen (35 microg ethinyl E2 daily on days 1 to 21)
Number of subjects: 42
Study: 1830916

Group type: EXPERIMENTAL
Intervention: Right atrial appendage removal (Group A, n = 11)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Right atrial appendage preserved (Group B, n = 12)
Number of subjects: 23
Study: 7150460

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Oxmetidine 200 mg
Number of subjects: 36
Study: 31950597

Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) with a dose of 66 Gy in 33 fractions from parallel opposed lateral beams.
Number of subjects: 1
Study: 30318868

Group type: EXPERIMENTAL
Intervention: Mindfulness Ambassador Program (MAP); 12-session facilitated group mindfulness-based intervention
Number of subjects: 21

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 21
Study: 28435464

Group type: EXPERIMENTAL
Intervention: Omalizumab 300 mg subcutaneously every 4 weeks for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 25801872

Group type: EXPERIMENTAL
Intervention: Intensive treatment (target SBP <140 mm Hg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Guideline-recommended treatment (SBP <180 mm Hg)
Number of subjects: 0
Study: 22841616

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the subthalamic nucleus (STN)
Number of subjects: 0
Study: 21496264

Group type: COMPARATOR
Intervention: Low omega-6 diet
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low omega-6 plus high omega-3 diet
Number of subjects: 40
Study: 18085742

Group type: EXPERIMENTAL
Intervention: Multidisciplinary education program including training in home‐based exercises and guidelines for leisure physical activity (PA)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control group received a booklet added to usual medical care
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Multidisciplinary education program
Number of subjects: 208
Study: 16792342

Group type: EXPERIMENTAL
Intervention: Single Bond (superficial dentin)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Single Bond (deep dentin)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: OptiBond Solo (superficial dentin)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: OptiBond Solo (deep dentin)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond 2V (superficial dentin)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond 2V (deep dentin)
Number of subjects: 30
Study: 14671251

Group type: EXPERIMENTAL
Intervention: Stroke patients
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 15
Study: 11704025

Group type: EXPERIMENTAL
Intervention: Over-dipping glaucoma patients
Number of subjects: 193

Group type: COMPARATOR
Intervention: Dippers
Number of subjects: 193

Group type: COMPARATOR
Intervention: Nondippers
Number of subjects: 193
Study: 9142148

Group type: EXPERIMENTAL
Intervention: Type I gastrojejunostomy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Type II gastrojejunostomy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Type III gastrojejunostomy
Number of subjects: 45
Study: 8184642

Group type: EXPERIMENTAL
Intervention: rt-PA (n = 156)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study: 2467139

Group type: EXPERIMENTAL
Intervention: Amlodipine (2.5-10.0 mg)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (25-100 mg)
Number of subjects: 139
Study: 28734923

Group type: EXPERIMENTAL
Intervention: Coronary CTA
Number of subjects: 238
Study: 27550722

Group type: COMPARATOR
Intervention: Intravenous antibiotics (cefmetazole) alone (IV-only group)
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Combined preoperative oral antibiotics (metronidazole and kanamycin) and perioperative intravenous antibiotics (cefmetazole) (oral/IV group)
Number of subjects: 515
Study: 23665990

Group type: EXPERIMENTAL
Intervention: Concomitant treatment (omeprazole 20 mg/12 h, amoxicillin 1 g/12 h, clarithromycin 500 mg/12 h, metronidazole 500 mg/12 h for 10 days)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Sequential treatment (omeprazole 20 mg/12 h and amoxicillin 1 g/12 h for 5 days, followed by omeprazole 20 mg/12 h, clarithromycin 500 mg/12 h, and metronidazole 500 mg/12 h for 5 days)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 338
Study: 22414838

Group type: EXPERIMENTAL
Intervention: ProTaper S1-S2-F1-F2
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: WaveOne Primary reciprocating files
Number of subjects: 30
Study: 20136804

Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oxytocin (5 IU after delivery)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 40
Study: 18806536

Group type: EXPERIMENTAL
Intervention: Intraoperative epidural analgesia during major thoracotomy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Patient-controlled thoracic epidural analgesia until thoracostomy tube removal
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pain levels during hospitalization and the first few postoperative months
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pain levels 48 weeks after surgery
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pain during the first few postoperative days
Number of subjects: 120
Study: 16868694

Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg b.i.d starting the day of surgery, discontinued 15 days after catheter removal.
Number of subjects: 27
Study: 12472790

Group type: EXPERIMENTAL
Intervention: AMG 073
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 10716688

Group type: EXPERIMENTAL
Intervention: Combination therapy of lamivudine 100 mg daily with alpha interferon 10 million units three times weekly for 16 weeks after pretreatment with lamivudine for eight weeks (n=75)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Alpha interferon 10 million units three times weekly for 16 weeks (n=69)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Lamivudine 100 mg daily for 52 weeks (n=82)
Number of subjects: 230
Study: 9374604

Group type: EXPERIMENTAL
Intervention: Co-witness information (incorrect)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suggestive questioning paired with incorrect co-witness information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delayed memory test (48 hours after initial questioning)
Number of subjects: 0
Study: 1555905

Group type: EXPERIMENTAL
Intervention: CHO-diet (65% carbohydrate)
Number of subjects: 7

Group type: COMPARATOR
Intervention: C-diet (39% carbohydrate)
Number of subjects: 7
Study: 3728926

Group type: EXPERIMENTAL
Intervention: Epidural morphine 4 mg + intravenous naloxone 2 mg for 12 hours
Number of subjects: 45

Group type: COMPARATOR
Intervention: Epidural morphine 4 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intravenous naloxone
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (10 mg morphine intramuscularly + 20 ml epidural saline)
Number of subjects: 45
Study: 29512481

Group type: EXPERIMENTAL
Intervention: DPIV 1 μg with alum, AS01E, or AS03B
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: DPIV 4 μg with alum
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: DPIV 1 μg + AS03B
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 100
Study: 27919234

Group type: EXPERIMENTAL
Intervention: Blended CBT (B-CBT) consisting of six face-to-face CBT sessions alternated with six to eight online modules (NoDep)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) defined as 12 sessions of face-to-face CBT
Number of subjects: 130
Study: 23446088

Group type: EXPERIMENTAL
Intervention: NGX-4010 treatment (up to 3, 60-minute treatments)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: NGX-4010 treatment
Number of subjects: 272
Study: 22723310

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study: 19164305

Group type: EXPERIMENTAL
Intervention: Flushing with water-soluble contrast medium (WSCM)
Number of subjects: 334

Group type: COMPARATOR
Intervention: No flushing (control group)
Number of subjects: 334
Study: 17563157

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 60
Study: 15361722

Group type: EXPERIMENTAL
Intervention: Cefdinir (14 mg/kg divided twice daily)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (45/6.4 mg/kg divided twice daily)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Cefdinir
Number of subjects: 425

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 425
Study: 11348041

Group type: EXPERIMENTAL
Intervention: Late reperfusion (n=22)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Non-reperfusion (n=22)
Number of subjects: 44
Study: 9730792

Group type: EXPERIMENTAL
Intervention: Histamine bronchial challenge in divers
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Bronchial challenge tests
Number of subjects: 59
Study: 7518981

Group type: EXPERIMENTAL
Intervention: Terazosin (10 mg once daily)
Number of subjects: 996

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 996
Study: 2574673

Group type: EXPERIMENTAL
Intervention: Ammonium chloride (urinary pH 5.2)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sodium hydrogen carbonate (urinary pH 7.8)
Number of subjects: 10
Study: 4597122

Group type: EXPERIMENTAL
Intervention: Metiamide
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Metiamide (infused intravenously or intraduodenally)
Number of subjects: 14
Study: 30992108

Group type: EXPERIMENTAL
Intervention: Audiovisual intervention (animated video)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standardized verbal instructions (control group)
Number of subjects: 40
Study: 27557589

Group type: EXPERIMENTAL
Intervention: 30% salicylic acid peels
Number of subjects: 40

Group type: COMPARATOR
Intervention: Jessner's solution peels
Number of subjects: 40
Study: 26577771

Group type: EXPERIMENTAL
Intervention: SB2
Number of subjects: 159

Group type: COMPARATOR
Intervention: EU‐sourced INF (EU‐INF)
Number of subjects: 159

Group type: COMPARATOR
Intervention: US‐sourced INF (US‐INF)
Number of subjects: 159
Study: 23192698

Group type: EXPERIMENTAL
Intervention: Alcohol ablation (AA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Repeated thermal radiofrequency ablation (RFA)
Number of subjects: 40
Study: 21355157

Group type: EXPERIMENTAL
Intervention: Acupuncture (GB 37, BL 1, BL 2, EX-HN 5, ST 2, GB 14, GB 1, GB 20, BL 18, BL 23, ST 40)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Medication (Vitamin C, Vitamin E, and Entodon)
Number of subjects: 84
Study: 19426524

Group type: EXPERIMENTAL
Intervention: Telephone-delivered secondary prevention program (ProActive Heart) consisting of up to 10 x 30 minute scripted telephone health coaching sessions, a ProActive Heart handbook, and an educational resource.
Number of subjects: 550

Group type: COMPARATOR
Intervention: Control group (details not specified in the abstract).
Number of subjects: 550
Study: 21468626

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) for 12 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Hormone therapy (HT) for 24 months
Number of subjects: 45
Study: 15754345

Group type: EXPERIMENTAL
Intervention: Purpose-designed needle and sampling technique
Number of subjects: 23
Study: 11896626

Group type: COMPARATOR
Intervention: CCND1 870A allele in familial cases
Number of subjects: 377

Group type: COMPARATOR
Intervention: CCND1 870A allele in sporadic cases
Number of subjects: 377

Group type: COMPARATOR
Intervention: CDH1 ‐160A/C genotypes
Number of subjects: 377

Group type: COMPARATOR
Intervention: Low expressing A allele of CDH1
Number of subjects: 377
Study: 9857532

Group type: EXPERIMENTAL
Intervention: Autovaccine
Number of subjects: 0
Study: 7833310

Group type: EXPERIMENTAL
Intervention: Standardised vaginal ultrasound technique
Number of subjects: 160
Study: 2211568

Group type: EXPERIMENTAL
Intervention: Buspirone 5 mg t.i.d.
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo t.i.d.
Number of subjects: 72
Study: 90215

Group type: EXPERIMENTAL
Intervention: Disodium dichloromethylene diphosphonate 1600 mg/day
Number of subjects: 19
Study: 30499312

Group type: EXPERIMENTAL
Intervention: Vitamin E-diffused highly crosslinked polyethylene (VEPE)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Moderately crosslinked and mechanically annealed ultra-high molecular weight polyethylene (ModXLPE)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Ceramic femoral heads
Number of subjects: 208

Group type: COMPARATOR
Intervention: Metal femoral heads
Number of subjects: 208
Study: 26036660

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 396
Study: 25903752

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC) using a blood pressure cuff with four cycles of 5 minutes of ischaemia followed by 5 minutes of reperfusion immediately before surgery.
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 400
Study: 23289548

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation (1,470 mg docosahexaenoic acid and 147 mg eicosapentaenoic acid daily)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation
Number of subjects: 140
Study: 20648913

Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 53

Group type: COMPARATOR
Intervention: Support group
Number of subjects: 53
Study: 18156429

Group type: EXPERIMENTAL
Intervention: Dietary fat screener (PFat)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Dietary fruit and vegetable screener (FVS)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 1-item question on fruit and vegetable intake
Number of subjects: 4
Study: 16897200

Group type: EXPERIMENTAL
Intervention: Epidural neuroplasty
Number of subjects: 99

Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 99
Study: 14703595

Group type: EXPERIMENTAL
Intervention: RDS infants who developed BPD
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: RDS infants (both BPD and non-BPD)
Number of subjects: 39

Group type: COMPARATOR
Intervention: RDS infants who did not develop BPD
Number of subjects: 39
Study: 11020623

Group type: EXPERIMENTAL
Intervention: Phaco chop technique
Number of subjects: 242

Group type: COMPARATOR
Intervention: Divide and conquer technique
Number of subjects: 242
Study: 8898139

Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 42

Group type: COMPARATOR
Intervention: Non-operative treatment
Number of subjects: 42
Study: 1832516

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (once a day for 4 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (for 4 days)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (after withdrawal)
Number of subjects: 8
Study: 7046331

Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 40

Group type: COMPARATOR
Intervention: Alcuronium
Number of subjects: 40
Study: 31878199

Group type: EXPERIMENTAL
Intervention: Viewing Sophora japonica
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Viewing Ginkgo biloba
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Viewing Platanus acerifolia
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Viewing Koelreuteria paniculata
Number of subjects: 150

Group type: COMPARATOR
Intervention: Indoor environment (control)
Number of subjects: 150
Study: 28272999

Group type: EXPERIMENTAL
Intervention: Longer duration of lifetime unemployment
Number of subjects: 1282
Study: 27503949

Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholic acid (TUDCA, 1500 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 24315572

Group type: EXPERIMENTAL
Intervention: Polysomnographic sleep during inpatient treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Participants with positive urine test
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Total sleep time (TST) compared to number of days abstinent
Number of subjects: 20
Study: 22699440

Group type: EXPERIMENTAL
Intervention: RIX4414
Number of subjects: 684

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 684
Study: 20142023

Group type: EXPERIMENTAL
Intervention: Ambrisentan monotherapy
Number of subjects: 12
Study: 18388356

Group type: EXPERIMENTAL
Intervention: Acetazolamide (Acz) 250 mg/d for 12 weeks
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Acetazolamide (Acz) 250 mg/d for 6 months (after a 4-week washout)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 15807672

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg/day on 3 consecutive days per week for the first month, 2 consecutive days per week for the second month, and 1 day per week for the third month.
Number of subjects: 51

Group type: COMPARATOR
Intervention: Doxycycline twice a day for the first month, once a day for the second and third months.
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 51

Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 51
Study: 12393820

Group type: EXPERIMENTAL
Intervention: Lumpectomy plus breast irradiation
Number of subjects: 1851

Group type: COMPARATOR
Intervention: Lumpectomy alone
Number of subjects: 1851

Group type: COMPARATOR
Intervention: Total mastectomy
Number of subjects: 1851

Group type: COMPARATOR
Intervention: Postoperative breast irradiation among lumpectomy-treated women with tumor-free margins
Number of subjects: 1851

Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 1851
Study: 12038039

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei and L. acidophilus strains CERELA (1.5 g each)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei and L. acidophilus strains CERELA
Number of subjects: 22
Study: 10217552

Group type: EXPERIMENTAL
Intervention: Contingent voucher incentives (n = 19) for each consecutive naltrexone dose ingested
Number of subjects: 58

Group type: COMPARATOR
Intervention: Non-contingent voucher incentives (n = 19) on unpredictable schedule
Number of subjects: 58

Group type: COMPARATOR
Intervention: No-voucher group (n = 20)
Number of subjects: 58
Study: 10158377

Group type: EXPERIMENTAL
Intervention: Atherectomy treatment of bifurcation lesions
Number of subjects: 1012

Group type: COMPARATOR
Intervention: Angioplasty treatment of bifurcation lesions
Number of subjects: 1012
Study: 2526999

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (220 mg Zn sulfate orally)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no zinc supplementation)
Number of subjects: 14
Study: 106965

Group type: EXPERIMENTAL
Intervention: sodium‐2‐mercaptoethane sulfonate (ASTA D‐7093; mesnum) administered intravenously to 11 patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: standard prophylaxis administered to 9 patients
Number of subjects: 20
Study: 31939923

Group type: EXPERIMENTAL
Intervention: Ultrathin Descemet Stripping Automated Endothelial Keratoplasty (UT‐DSAEK)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Descemet Membrane Endothelial Keratoplasty (DMEK)
Number of subjects: 38
Study: 30610021

Group type: EXPERIMENTAL
Intervention: MSMW
Number of subjects: 1809

Group type: COMPARATOR
Intervention: MSMO
Number of subjects: 1809
Study: 29179734

Group type: EXPERIMENTAL
Intervention: Digital cessation intervention (WEB + TXT)
Number of subjects: 1650

Group type: EXPERIMENTAL
Intervention: Digital cessation intervention combined with tobacco treatment specialist (TTS) counseling (WEB + TXT + TTS)
Number of subjects: 1650

Group type: COMPARATOR
Intervention: Usual care control condition (UC) which consists of Ask-Advise-Refer
Number of subjects: 1650
Study: 25754008

Group type: EXPERIMENTAL
Intervention: FEMTO LDV Crystal Line femtosecond laser and WaveLight Allegretto Eye‐Q 400 Hz excimer laser
Number of subjects: 444
Study: 23332672

Group type: EXPERIMENTAL
Intervention: 2-year multidomain intervention consisting of nutritional guidance, exercise, cognitive training and social activity, and management of metabolic and vascular risk factors
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Regular health advice
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: 2-year multidomain intervention
Number of subjects: 1200
Study: 21855592

Group type: EXPERIMENTAL
Intervention: 9 μg ID-TIV
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: 15 μg ID-TIV
Number of subjects: 112

Group type: COMPARATOR
Intervention: 15 μg IM VA-TIV
Number of subjects: 112